Henry Schein Inc (HSIC) FinancialsHSICHenry Schein Inc

Henry Schein, Inc. (HSIC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Global distribution and ValueAdded services, accounting for 84.0% of total sales, equivalent to $2.90B. Other significant revenue streams include Global Speciality Products and Global Technology. Understanding this composition is critical for investors evaluating how HSIC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Henry Schein, Inc. maintains a gross margin of 29.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.81%, while the net margin is 2.95%. These profitability ratios, combined with a Return on Equity (ROE) of 12.21%, provide a clear picture of how effectively HSIC converts its operational activities into shareholder value.

In the context of the broader market, HSIC competes directly with industry leaders such as MYO and MEDS. With a market capitalization of $9.69B, it holds a leading position in the sector. When comparing efficiency, HSIC's gross margin of 29.81% stands against MYO's 72.13% and MEDS's -9.80%. Such benchmarking helps identify whether Henry Schein, Inc. is trading at a premium or discount relative to its financial performance.

Henry Schein has demonstrated consistent revenue growth, with Q2 2026 revenue at $3.458 billion, up from $3.240 billion in the previous year. The gross margin has remained stable around 29.81% in Q2 2026, indicating solid profitability. The company also reported a net income of $94 million for Q2 2026, translating to an EPS of $0.82, up from $0.70 in the previous year.